AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...

AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

NORTH CHICAGO, Ill. - Pharmaceutical (TADAWUL:2070) giant AbbVie (NYSE:ABBV), a $339 billion market cap company with a strong financial health rating according to InvestingPro, and biotech firm Xilio ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Emblaveo is a fixed-dose IV treatment that combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

The global research agenda includes 33 research priorities for bacterial and fungal infections and 7 for drug-resistant ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

Addresses the significant threat of antimicrobial resistance.